一名31岁的加尔各答人在印度东部首次成功接受印度制造的白血病CAR-T治疗。 A 31-year-old in Kolkata becomes first in Eastern India to successfully receive India-made CAR-T therapy for leukemia.

在印度加尔各答,一名31岁的工程师成为印度东部第一个成功在阿波罗多专业医院接受CAR-T细胞疗法的成人病人,治疗B型急性淋巴菌性白血病。 A 31-year-old engineer in Kolkata, India, became the first adult patient in Eastern India to successfully receive CAR-T cell therapy for high-risk Pre-B Acute Lymphoblastic Leukemia at Apollo Multispeciality Hospitals. 医生建议使用印度开发的产品NexCAR19进行CAR-T治疗。 After initial treatment with chemotherapy failed to eliminate residual disease, doctors recommended CAR-T therapy using NexCAR19, an India-developed product. 该病人接受了预处理,并于2025年6月18日接受了注入,有轻微副作用,没有神经毒性。 The patient underwent pre-treatment and received the infusion on June 18, 2025, with mild side effects and no neurotoxicity. 医生们将结果称为一个里程碑,表明当地生产的CAR-T疗法在推进印度个人化癌症护理方面的安全和有效性。 Doctors called the outcome a milestone, demonstrating the safety and effectiveness of locally produced CAR-T therapy in advancing personalized cancer care in India.